Medical Equipment & Devices

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

Shares in ResMed seem positioned for a new 2024 high, reports Michael Gable of Fairmont Equities

Mar 19 2024

The New Criterion’s Tim Boreham explains the business case for Cochlear

Feb 28 2024


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
4DX 4DMEDICAL LIMITED $0.60 $1.27 $0.45

$1.15

CAT CATAPULT GROUP INTERNATIONAL LIMITED $1.51 $1.70 $0.69

$1.50

COH COCHLEAR LIMITED $318.89 $350.17 $220.40 52.5

$257.75

CU6 COCHLEAR LIMITED $2.71 $3.06 $0.68

$3.90

CYC CYCLOPHARM LIMITED $1.79 $3.15 $1.72

$3.80

EBR EBR SYSTEMS INC $0.85 $xx.xx $xx.xx xx.x xx.xx
FPH FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED $24.37 $xx.xx $xx.xx xx.x xx.xx
IDX INTEGRAL DIAGNOSTICS LIMITED $2.48 $xx.xx $xx.xx xx.x xx.xx
IME IMEXHS LIMITED $0.55 $xx.xx $xx.xx xx.x xx.xx
IMR IMRICOR MEDICAL SYSTEMS INC $0.51 $xx.xx $xx.xx xx.x xx.xx
IPD IMPEDIMED LIMITED $0.10 $xx.xx $xx.xx xx.x xx.xx
MX1 MICRO-X LIMITED $0.10 $xx.xx $xx.xx xx.x xx.xx
NAN NANOSONICS LIMITED $2.78 $xx.xx $xx.xx xx.x xx.xx
PGC PARAGON CARE LIMITED $0.33 $xx.xx $xx.xx xx.x xx.xx
PME PRO MEDICUS LIMITED $102.09 $xx.xx $xx.xx xx.x xx.xx
RMD RESMED INC $27.63 $xx.xx $xx.xx xx.x xx.xx
TRJ TRAJAN GROUP HOLDINGS LIMITED $1.15 $xx.xx $xx.xx xx.x xx.xx
VHT VOLPARA HEALTH TECHNOLOGIES LIMITED $1.14 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024

It has become the 'unofficial' tradition in recent years: an interview with Livewire Markets ahead of yet another corporate reporting…


Dr Boreham’s Crucible: Artrya

Feb 15 2024

Artificial intelligence and some valuable experiences should benefit heart device developer Artrya, Tim Boreham explains


ResMed Recovery Turns Into Hollywood Script

Jan 31 2024

More troubles for key competitor Philips/Respironics suggests there could be more momentum shifting in ResMed’s favour


ResMed Makes A Comeback

Jan 29 2024

ResMed’s December quarter showed long-awaited margin improvement and relieved market fears of the impact of weight-loss drugs


ResMed: The Recovery Has Begun

Jan 23 2024

Michael Gable of Fairmont Equities observes market dynamics for ResMed have changed for the better with price action suggesting higher prices are on the cards


Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023

Tim Boreham highlights the significance of a new contract win for Pro Medicus and the company’s AI capacity


Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023

FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports


Dr Boreham’s Crucible: Painchek

Sep 11 2023

Tim Boreham highlights a device used to detect pain in non-verbal patients, such as those suffering dementia and infants


Margins Signal Integral Diagnostics Recovery

Sep 07 2023

Analysts identify a second half FY23 inflection point for Integral Diagnostics


ResMed: Finding A Base?

Aug 15 2023

After a sharp pullback for ResMed, Michael Gable of Fairmont Equities suggests a base may soon be formed, providing a buying opportunity